BR112020022430A2 - métodos para tratamento de linfoma - Google Patents

métodos para tratamento de linfoma Download PDF

Info

Publication number
BR112020022430A2
BR112020022430A2 BR112020022430-8A BR112020022430A BR112020022430A2 BR 112020022430 A2 BR112020022430 A2 BR 112020022430A2 BR 112020022430 A BR112020022430 A BR 112020022430A BR 112020022430 A2 BR112020022430 A2 BR 112020022430A2
Authority
BR
Brazil
Prior art keywords
lymphoma
cerdulatinib
patient
effective amount
cell lymphoma
Prior art date
Application number
BR112020022430-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Gregory Coffey
Matthew Birrell
Pamela B. Conley
John T. Curnutte
Anjali Pandey
Andrew Steele
Glenn Michelson
Original Assignee
Portola Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharmaceuticals, Inc. filed Critical Portola Pharmaceuticals, Inc.
Publication of BR112020022430A2 publication Critical patent/BR112020022430A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112020022430-8A 2018-05-04 2019-05-03 métodos para tratamento de linfoma BR112020022430A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862667249P 2018-05-04 2018-05-04
US62/667,249 2018-05-04
US201862678934P 2018-05-31 2018-05-31
US62/678,934 2018-05-31
US201862736047P 2018-09-25 2018-09-25
US62/736,047 2018-09-25
PCT/US2019/030690 WO2019213589A1 (en) 2018-05-04 2019-05-03 Methods for treating lymphoma

Publications (1)

Publication Number Publication Date
BR112020022430A2 true BR112020022430A2 (pt) 2021-02-09

Family

ID=66554509

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020022430-8A BR112020022430A2 (pt) 2018-05-04 2019-05-03 métodos para tratamento de linfoma

Country Status (11)

Country Link
US (3) US11266645B2 (cg-RX-API-DMAC7.html)
EP (1) EP3787628A1 (cg-RX-API-DMAC7.html)
JP (2) JP2021523114A (cg-RX-API-DMAC7.html)
KR (1) KR20210003789A (cg-RX-API-DMAC7.html)
CN (1) CN112074271B (cg-RX-API-DMAC7.html)
AU (1) AU2019262644A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020022430A2 (cg-RX-API-DMAC7.html)
CA (1) CA3098012A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020011817A (cg-RX-API-DMAC7.html)
TW (1) TW202014190A (cg-RX-API-DMAC7.html)
WO (1) WO2019213589A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851087B2 (en) 2018-05-04 2020-12-01 Portola Pharmaceuticals, Inc. Synthesis of cerdulatinib
WO2019213606A2 (en) 2018-05-04 2019-11-07 Portola Pharmaceuticals, Inc. Solid forms of cerdulatinib
KR20230078997A (ko) * 2020-08-27 2023-06-05 르 라보레또레 쎄르비에르 병용 암 요법에서의 dhodh 저해제 화합물의 용도
EP4436581A4 (en) * 2021-11-22 2025-08-13 Secura Bio Inc METHODS OF TREATING PERIPHERAL T-CELL LYMPHOMA
CN114306606B (zh) * 2021-11-29 2023-05-26 江苏省人民医院(南京医科大学第一附属医院) cGAS抑制剂在制备治疗T细胞淋巴瘤的药物中的应用
CN115177620A (zh) * 2022-07-18 2022-10-14 厦门大学附属第一医院 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用
WO2024115935A1 (en) * 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors
CN117427166B (zh) * 2023-09-25 2024-09-10 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) Csf1r抑制剂用于制备nk/t细胞淋巴瘤治疗药物的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
CA2594542C (en) 2005-01-10 2014-03-25 University Of Virginia Patent Foundation Synthesis of inhibitors of p90rsk
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders
WO2016196385A1 (en) * 2015-05-29 2016-12-08 Portola Pharmaceuticals, Inc. Cerdulatinib for the treatment of b-cell malignancies
EP3383396B1 (en) * 2015-12-04 2023-07-12 Alexion Pharmaceuticals, Inc. Cerdulatinib and venetoclax for treating non-hodgkin's lymphoma

Also Published As

Publication number Publication date
KR20210003789A (ko) 2021-01-12
WO2019213589A1 (en) 2019-11-07
US20250213562A1 (en) 2025-07-03
JP2024024093A (ja) 2024-02-21
CN112074271A (zh) 2020-12-11
US20200061060A1 (en) 2020-02-27
MX2020011817A (es) 2021-02-26
TW202014190A (zh) 2020-04-16
CA3098012A1 (en) 2019-11-07
CN112074271B (zh) 2023-10-20
JP2021523114A (ja) 2021-09-02
US20220233533A1 (en) 2022-07-28
AU2019262644A1 (en) 2020-11-12
EP3787628A1 (en) 2021-03-10
US11266645B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
US20250213562A1 (en) Methods for treating lymphoma
RU2737496C2 (ru) Способы лечения рака
JP6588515B2 (ja) ブルトン型チロシンキナーゼ(Btk)阻害剤の使用
US20200138829A1 (en) Methods of cancer treatment
CN110536703B (zh) 使用抗axl抗体-药物缀合物的组合疗法
ES2958412T3 (es) Cerdulatinib para el tratamiento de tumores malignos de linfocitos B
ES2959692T3 (es) Cerdulatinib y venetoclax para tratar linfoma no Hodgkin
US20250049810A1 (en) Methods of treating a ras protein-related disease or disorder
JP2018522910A (ja) 骨髄腫を治療するためのセルデュラチニブ(cerdulatinib)
TW201815392A (zh) 用於癌症治療之考比西他 (cobicistat)
Chu et al. Recent research progress of chiral small molecular antitumor-targeted drugs approved by the FDA from 2011 to 2019
CN114302745A (zh) 包含抗cd19抗体药物缀合物以及pi3k抑制剂或第二剂的组合疗法
BR112020018184A2 (pt) usos de compostos
CN113747895A (zh) 包含pkm2调节剂的组合物和用其治疗的方法
JP2020023497A (ja) 組合せ医薬
RU2784243C2 (ru) Способы лечения лимфомы
US20230181581A1 (en) Circulating b cell subpopulations in indolent b cell lymphoma
KR20230010659A (ko) Sumo-활성화 효소 억제제 및 항-cd38 항체의 투여
WO2025233224A1 (en) Use of atr inhibitors in combination with anti-pd(l)1 therapy
WO2025237957A1 (en) Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
Mom Exploring targeted therapies in oncology
NZ750372B2 (en) Cobicistat for use in cancer treatments
HK1226957A1 (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]